Form 4: AIM ImmunoTech CEO Acquires Shares and Disposes of Shares in Recent Transaction
SEC Form 4 Filing
Thomas K. Equels, CEO and President of AIM ImmunoTech Inc., reports acquiring 377,358 shares of common stock at $0.265 per share and disposing of 1,155,542 shares on August 12, 2024.
Summary
- On August 12, 2024, Thomas K. Equels, the CEO and President of AIM ImmunoTech Inc., engaged in a transaction involving the company's common stock.
- Equels acquired 377,358 shares at a price of $0.265 per share.
- Simultaneously, Equels disposed of 1,155,542 shares.
- Following these transactions, the total number of common stock shares beneficially owned by Equels is not specified in this document.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting stock transactions by a company insider. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, like the CEO, who trade in their company's stock. It provides transparency to the market regarding the transactions of company leadership.
Stakeholder Impact
- Shareholders may react to the CEO's stock transactions, potentially influencing the stock price.
Key Dates
| Date | Description |
|---|---|
| 08/12/2024 | Date of the transaction: acquisition and disposition of AIM ImmunoTech Inc. common stock by Thomas K. Equels. |
Keywords
AIM ImmunoTech Inc., Thomas K. Equels, Common Stock, Acquisition, Disposition, Form 4, SEC, CEO, President
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.